Regulatory progress in Japan is welcome but US industry wants more
This article was originally published in SRA
Executive Summary
Progress in the regulatory area in Japan in recent years has helped to speed up new product approvals and encourage participation in multinational clinical trials, but further improvements are needed in a number of areas, the US research-based industry association PhRMA maintains1.